

# JAGADISHWAR

## PHARMACEUTICAL WORKS LIMITED

CIN : L24232AS1987PLC002803

**Regd. Off.:** 205, Haribol Roy Market, 2<sup>nd</sup> Floor, A.T.Road, Guwahati -781001

**Corp. Off.:** 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Website: jagadishwarpharma.com

E\_mail ID: [jpwltd@yahoo.com](mailto:jpwltd@yahoo.com)

Phone No.: +91 9163513015

**Date: August 12, 2025**

To,  
Head- Listing & Compliance  
Metropolitan Stock Exchange of India Ltd. (MSEI),  
205(A), 2<sup>nd</sup> Floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West),  
Mumbai – 400 070

**Dear Sir,**

**Sub: Outcome of the Board Meeting held on today, 12<sup>th</sup> August 2025**

Please note that the Board of Directors of the Company at its meeting held today, which commenced at 2.45 p.m. and concluded at 3.15 p.m. as inter alia transacted the following business (es):

1. Considered, approved and adopted the Un-audited Financial Results for the quarter ended 30<sup>th</sup> June, 2025. A copy of Un-audited Financial Results for the quarter ended 30<sup>th</sup> June, 2025 alongwith Limited Review Report of the Company is enclosed;

Kindly take the same on your record and oblige.

Thanking You,

**For Jagadishwar Pharmaceutical Works Limited**

*Swapan Sarkar*  
Swapan Sarkar  
Executive Director  
(DIN: 05149442)



**Encl: As above**

# Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

**Regd. Office:** 205, Haribol Roy Market, A.T.Road, 2nd Floor, Near Saraf Building, Guwahati - 781 001

**Corp. Office :** 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

**Email ID:** jpwlttd@yahoo.com    **Website:** jagadishwarpharma.com    **Tel:** +91 9163513015


## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.25	31.03.25	30.06.24	31.03.25
		Unaudited	Audited	Unaudited	Audited
<b>1</b>	<b>Income From Operations</b>				
	(a) Net Sales / Income from Operations	-	-	-	-
	(b) Other Operating Income	9.077	6.325	6.195	25.080
	<b>Total Income from Operations</b>	<b>9.077</b>	<b>6.325</b>	<b>6.195</b>	<b>25.080</b>
<b>2</b>	<b>Expenses</b>				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchase of stock-in-trade	-	5.075	-	12.325
	(c) Changes in inventories of finished goods, work-	-	(5.075)	-	(12.325)
	(d) Employee benefits expense	7.319	7.012	7.320	35.128
	(e) Depreciation and amortisation expense	-	0.166	-	0.166
	(f) Finance Cost	-	-	-	-
	(g) Other expenses	4.175	2.217	4.406	8.674
	<b>Total Expenses</b>	<b>11.494</b>	<b>9.395</b>	<b>11.727</b>	<b>43.968</b>
<b>3</b>	<b>exceptional items (1-2)</b>	<b>(2.418)</b>	<b>(3.070)</b>	<b>(5.531)</b>	<b>(18.888)</b>
<b>4</b>	<b>Other Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)</b>	<b>(2.418)</b>	<b>(3.070)</b>	<b>(5.531)</b>	<b>(18.888)</b>
<b>6</b>	<b>Finance Costs</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>7</b>	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>(2.418)</b>	<b>(3.070)</b>	<b>(5.531)</b>	<b>(18.888)</b>
<b>8</b>	<b>Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9</b>	<b>Profit / (Loss) from ordinary activities before tax (7-8)</b>	<b>(2.418)</b>	<b>(3.070)</b>	<b>(5.531)</b>	<b>(18.888)</b>
<b>10</b>	<b>Tax Expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>11</b>	<b>Net Profit / (Loss) from ordinary activities after tax (9-10)</b>	<b>(2.418)</b>	<b>(3.070)</b>	<b>(5.531)</b>	<b>(18.888)</b>
<b>12</b>	<b>Extraordinary item (net of tax Rs. Nil Lakhs)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>13</b>	<b>Net Profit / (Loss) for the period (11-12)</b>	<b>(2.418)</b>	<b>(3.070)</b>	<b>(5.531)</b>	<b>(18.888)</b>
<b>14</b>	<b>Share of Profit / (loss) of associates</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>15</b>	<b>Minority Interest</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>16</b>	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13-14-15)</b>	<b>(2.418)</b>	<b>(3.070)</b>	<b>(5.531)</b>	<b>(18.888)</b>
<b>17</b>	<b>Other Comprehensive Income</b>	<b>-</b>	<b>12.271</b>	<b>-</b>	<b>12.271</b>
<b>18</b>	<b>Total Comprehensive Income</b>	<b>(2.418)</b>	<b>9.201</b>	<b>(5.531)</b>	<b>(6.617)</b>
<b>19</b>	<b>Paid-up Equity Share Capital (Face Value of Rs.10/- per Share)</b>	<b>2,970.02</b>	<b>2,970.02</b>	<b>2,970.02</b>	<b>2,970.02</b>
<b>20</b>	<b>Reserves (excluding Revaluation Reserve) as shown in the Audited Balance</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>138.95</b>
<b>21.i</b>	<b>Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)</b>				
	(a) Basic	-	0.03	-	-
	(b) Diluted	-	0.03	-	-
<b>21.ii</b>	<b>Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)</b>				
	(a) Basic	-	0.03	-	-
	(b) Diluted	-	0.03	-	-

### Notes :

- The figures for the corresponding previous periods have been restated / regrouped, wherever necessary, to make them comparable.
- These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Audit Committee reviewed the above results. The Board of Directors at its meeting held on 12th August, 2025, approved the above results. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company does not have any reportable segment as per Indian Accounting Standard "Operating Segment" (Ind AS-108). Accordingly, segment reporting is not applicable.

For Jagadishwar Pharmaceutical Works Ltd.



**Swapan Sarkar**  
Director  
(DIN : 05149442)

Date : 12/08/2025

Place: Kolkata





Review report to Jagadishwar Pharmaceutical Works Limited

We have reviewed the accompanying statement of unaudited financial results of Jagadishwar Pharmaceutical Works Limited (Name of the Company) for the period ended 30<sup>th</sup> June 2025. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For **Rajesh U Shah & Associates**  
Chartered Accountants



  
**Rajesh Shah**

Proprietor

Membership Number: 056550

Firm Regn. No.: 327799E

UDIN: 25056550BM0MAR992

Place: Kolkata

Date: August 12, 2025